---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-012373"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:32:43.843764+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics reports FY 2023 net loss of $71.9M; topline data expected Q4 2024 for Advance-HTN

## Summary
- Net loss of $71.9M for FY 2023 vs $29.8M in 2022; R&D expenses increased to $70.4M.
- Cash, cash equivalents and investments $239.0M at Dec 31, 2023; subsequent private placement raised ~$120M.
- Entered into ATM equity offering sales agreement to sell up to $100M of common stock.
- Pivotal Advance-HTN trial topline data expected Q4 2024; Launch-HTN data in 2H 2025.
- Explore-CKD Phase 2 trial design modified; topline data expected Q4 2024 to Q1 2025.

## SEC filing metadata
- accession: 0001628280-24-012373
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000162828024012373/0001628280-24-012373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000162828024012373/mlys-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-012373
- JSON: https://secwatch.observer/filing/0001628280-24-012373.json
- Plain text: https://secwatch.observer/filing/0001628280-24-012373.txt

## Key facts
- Earnings Releases
  Mineralys Therapeutics, Inc. reported quarter and fiscal year ended December 31, 2023 results: net income Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 3.
  - Period: quarter and fiscal year ended December 31, 2023
  - Net income: Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 3
  - Result: reported results
  source text: Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000162828024012373/0001628280-24-012373-index.htm
- Material Agreements
  Mineralys Therapeutics, Inc. entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. and Evercore Group L.L.C. valued at $100,000,000 (effective 2024-03-21).
  - Action: entry
  - Agreement: atm program
  - Counterparty: BofA Securities, Inc. and Evercore Group L.L.C.
  - Value: $100,000,000
  - Effective: 2024-03-21
  source text: On March 21, 2024, Mineralys Therapeutics, Inc. (the “Company”), entered into an ATM Equity Offering Sales Agreement (the “Agreement”) with BofA Securities, Inc. and Evercore Group L.L.C. as the Company’s sales agents (the “Agents”) and/or principals. Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company’s common stock having an aggregate offering price of up to $100,000,000 (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000162828024012373/0001628280-24-012373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.